New insights on chemically induced animal models of systemic sclerosis

Current Opinion in Rheumatology

Volumn 23, Issue 6, 2011, Pages 511-518

  Batteux, Frédéric ^a   Kavian, Niloufar ^a   Servettaz, Amélie ^a,b  

^a UPRES EA 1833   (France)

^b Faculté de Mé Decine de Reims   (France)

Author keywords

Animal models; Bleomycin; Reactive oxygen species; Systemic sclerosis

Indexed keywords

BLEOMYCIN; GAMMA INTERFERON; HYPOCHLOROUS ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; L SELECTIN; NOTCH RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FIBROSIS; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; SYSTEMIC SCLEROSIS; TH1 CELL; TH17 CELL; TH2 CELL; VASCULAR DISEASE;

ANIMALS; AUTOIMMUNITY; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; HYPOCHLOROUS ACID; INFLAMMATION; MICE; REACTIVE OXYGEN SPECIES; SCLERODERMA, SYSTEMIC;

EID: 82955219594     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834b1606     Document Type: Review

References (74)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26:587-595. (Pubitemid 41726446)
2. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62:2831-2844.
3. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011; 63:1707-1717.
4. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98:785-792. (Pubitemid 26349184)
5. Worda M, Sgonc R, Dietrich H, et al. In vivo analysis of the apoptosisinducing effect of antiendothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003; 48:2605-2614. (Pubitemid 37129437)
6. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112:456-462. (Pubitemid 29171935)
7. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292:535-541. (Pubitemid 32003036)
8. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V: Increased expression of a-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002; 102:77-83. (Pubitemid 34095227)
9. Yamamoto T, Takahashi Y, Takagawa S, et al. Animal model of sclerotic skin. II: Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1- W/W(V) mice. J Rheumatol 1999; 26:2628-2634.
10. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001; 117:999-1001. (Pubitemid 33001228)
11. Yamamoto T, Nishioka K. Animal model of sclerotic skin. VI: Evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 2004; 295:453-456. (Pubitemid 38468669)
12. Yoshizaki A, Iwata Y, Komura K, et al. CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172:1650-1663. (Pubitemid 351793356)
13. Ishikawa H, Takeda K, Okamoto A, et al. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4 T cells. J Invest Dermatol 2009; 129:1688-1695.
14. Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycininduced murine scleroderma: current update and future perspective. Exp Dermatol 2005; 14:81-95. (Pubitemid 40277574)
15. Oi M, Yamamoto T, Nishioka K. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J Med Dent Sci 2004; 51:7-17. (Pubitemid 41114818)
16. Takagawa S, Lakos G, Mori Y, et al. Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003; 121:41-50. (Pubitemid 36900453)
17. Bhattacharyya S, Ghosh AK, Pannu J, et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005; 52:1248-1258. (Pubitemid 40530133)
18. Mori Y, Hinchcliff M, Wu M, et al. Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp Cell Res 2008; 314:1094-1104.
19. Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/ Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004; 165:203-217. (Pubitemid 38821828)
20. Hasegawa M, Matsushita Y, Horikawa M, et al. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis. Arthritis Rheum 2009; 60:3465-3475.
21. Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006; 281:21183-21197. (Pubitemid 44115458)
22. Bhattacharyya S, Wei J, Melichian DS, et al. The transcriptional cofactor Nab2 is induced by TGF-Beta and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma. PLoS One 2009; 4: e7620.
23. Jakobsson PJ, Thoren S, Morgenstern R, et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999; 96:7220-7225. (Pubitemid 29299642)
24. Stichtenoth DO, Thoren S, Bian H, et al. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 2001; 167:469-474. (Pubitemid 32567813)
25. McCann MR, Monemdjou R, Ghassemi-Kakroodi P, et al. mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther 2011; 13:R6.
26. Galindo M, Santiago B, Alcami J, et al. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 2001; 123:36-41. (Pubitemid 32118834)
27. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003; 121:510-516. (Pubitemid 37072262)
28. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor b1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271:17779-17784. (Pubitemid 26250752)
29. Ferreira AM, Takagawa S, Fresco R, et al. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006; 126:1900-1908. (Pubitemid 44086526)
30. Kaplan MH. STAT4: a critical regulator of inflammation in vivo. Immunol Res 2005; 31:231-242.
31. Dieudé P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60:2472-2479.
32. Avouac J, Fürnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011; 63:800-809.
33. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009; 60:1129-1136.
34. Servettaz A, Kavian N, Nicco C, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 2010; 177:187-196.
35. Balistreri E, Garcia-Gonzalez E, Selvi E, et al. The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann Rheum Dis 2011; 70:695-699.
36. Marquart S, Zerr P, Akhmetshina A, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010; 62:3467-3476.
37. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007; 19:574-579. (Pubitemid 47530878)
38. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208:961-972.
39. Makhluf HA, Stepniakowska J, Hoffman S, et al. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 1996; 107:856-859. (Pubitemid 26408204)
40. Postlethwaite AE, Holness MA, Katai H, et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992; 90:1479-1485.
41. 4 T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J Immunol 1998; 160:5719-5728. (Pubitemid 28298027)
42. Needlemann BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin- 4, interleukin-6, tumor necrosis factor a, and interferon-c levels in sera from patients with scleroderma. Arthritis Rheum 1985; 28:775-780.
43. Yamamoto T, Takagawa S, Katayama I, et al. Antisclerotic effect of antitransforming growth factor b antibody in bleomycin-induced scleroderma. Clin Immunol 1999; 92:6-13. (Pubitemid 29315981)
44. Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol 2004; 135:348-356. (Pubitemid 40082202)
45. Lakos G, Melichian D, Wu M, et al. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006; 73:224-237. (Pubitemid 46332830)
46. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007; 104:2827-2930.
47. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101:2129-2139. (Pubitemid 28244097)
48. Jinnin M, Ihn H, Yamane K, et al. Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004; 279:41783-41791. (Pubitemid 39313625)
49. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998; 10:1421-1433. (Pubitemid 28451436)
50. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor b1. J Exp Med 2001; 194:809-821. (Pubitemid 32983016)
51. Sato S, Fujimoto M, Hasegawa M, et al. Altered blood B lymphocyte homeostasis in systemic sclerosis. Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2001; 50:918-927.
52. Tanaka C, Fujimoto M, Hamaguchi Y, et al. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis Rheum 2010; 62:1723-1732.
53. Liu S, Kapoor M, Denton CP, et al. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009; 60:2817-2821.
54. Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185:2502-2515.
55. Yoshizaki A, Yanaba K, Yoshizaki A, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62:2476-2487.
56. Ozgen M, Koca SS, Isik A, et al. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma. J Rheumatol 2010; 37:678-679.
57. Allanore Y, Borderie D, Lemarechal H, et al. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004; 116:595-600. (Pubitemid 38490533)
58. Simonini G, Matucci Cerinic M, Generini S, et al. Oxidative stress in systemic sclerosis. Mol Cell Biochem 1999; 196:85-91. (Pubitemid 29338782)
59. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001; 19:4-8. (Pubitemid 32203838)
60. Servettaz A, Guilpain P, Goulvestre C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007; 66:1202-1209. (Pubitemid 47309738)
61. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive upregulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44:2653-2664. (Pubitemid 33049343)
62. Ogawa F, Shimizu K, Muroi E, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45:815-818. (Pubitemid 43985368)
63. Herrick AL, Rieley F, Schofield D, et al. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994; 21:1477-1483. (Pubitemid 24261532)
64. Sambo P, Jannino L, Candela M, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112:78-84. (Pubitemid 29024710)
65. Svegliati Baroni S, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354:2667-2676.
66. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997; 185:71-79. (Pubitemid 27039442)
67. Servettaz A, Goulvestre C, Kavian N, et al. Selective oxidation of DNA topoisomerase 1 induced systemic sclerosis in the mouse. J Immunol 2009; 182:5855-5864.
68. Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 2010; 62:3477-3487.
69. Bellocq A, Azoulay E, Marullo S, et al. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999; 21:128-136. (Pubitemid 129508636)
70. Svegliati S, Cancello R, Sambo P, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. J Biol Chem 2005; 280:36474-36482. (Pubitemid 41633921)
71. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011; 63:1396-1404.
72. Davies CD, Jeziorska M, Freemont AJ, et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006; 37:190-197.
73. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4:R11.
74. Gay S, Jones JRE, Huang GQ, et al. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92:301-303. (Pubitemid 19061278)